Safety and efficacy of tyrosine kinase inhibitors for the treatment of severe and progressive pulmonary hypertension

Trial Profile

Safety and efficacy of tyrosine kinase inhibitors for the treatment of severe and progressive pulmonary hypertension

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2015

At a glance

  • Drugs Imatinib (Primary) ; Sorafenib (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan record.
    • 18 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top